Analysts are bullish on Gilead Sciences, which recently sold $1.3 billion in debentures to fund new licensing deals and acquisitions. Gilead, which is receiving a substantial revenue stream from Roche for Tamiflu, has a deal to buy the remaining shares of Corus Pharma following Phase III data.
- read the Forbes report [1] for more information
PLUS: Bristol-Myers Squibb and Gilead have filed for approval of a once-daily HIV treatment that combines Sustiva and Truvada. Report [2]
Links:
[1] http://www.forbes.com/markets/2006/04/27/gilead-bristol-myers-0427markets01.html
[2] http://today.reuters.com/investing/financeArticle.aspx?type=marketsNews&storyID=2006-04-27T114517Z_01_WEN5889_RTRIDST_0_HEALTH-GILEAD-HIV-URGENT.XML